| |
 |
Vioptix
Applications |
 |
 |
 |
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
Manifestations
of PVD |
 |
 |
 |
 |
 |

PVC FACTS: Over
10 million Americans affected in the US, growing at 5%/yr.
Affects
20% of the elderly (>70 y.o) and 40% of Diabetics
Grossly underdiagnosed: 71% of Physicians overlook condition
in their patients Patients
with PVD are 4 times more likely to have an infarct and 3 times
more likely to have a stroke. 5-yr
mortality: 30% (Compared with 18% for Hodgkin’s and 15%
for Breast Ca) |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
PORH
StO2 Curve |
 |
 |
 |
 |
 |

enlarge
|
 |
 |
 |
 |
 |
 |
 |
|
|
Peripheral Vascular Disease - PVD
PVD is a common circulatory disease in which the arteries that carry
blood to the legs or arms become narrowed or clogged. The most common
cause is atherosclerosis, or hardening of the arteries. The disease
causes compromised blood flow, which manifests as claudication (leg
pain after exercise). It may be acutely compounded by either emboli
or thrombi, and patients are at higher risk for heart disease and
stroke. In advanced cases, the patient may feel burning or aching
pain in the foot and toes while resting, and ulcers may develop.
Untreated PVD can lead to gangrene, a serious condition that may
require amputation of a leg, foot or toes. PVD is a chronic, progressive
and debilitating disease of nearly pandemic proportion. Risk factors
for PVD include high cholesterol, hypertension, diabetes, smoking,
obesity or history of cardiovascular disease.
Statistics:
• It is estimated that PVD affects 10 million patients in
the US
• Incidence is expected to increase significantly over the
next several years as the population ages.
• Between 20 and 30 per cent of patients over 60 years of
age have PVD.
• Approximately 30 per cent of patients will ultimately require
open surgical or percutaneous revascularization. The five-year mortality
rate for patients with PVD approaches 30 per cent
• Life expectancy of PVD patients is reduced by 10 years
Clinical Value:
The ODISsey Tissue Oximeter takes direct measurement of tissue oxygen
saturation levels in real time. It is easy
for physicians to use and provides a quick, reliable measurement,
non-invasively. The Company expects ODISsey to quickly become the
standard of care for screening, diagnosing and monitoring PVD patients.
Note: Some of the applications
discussed in the Application and Future Applications section are
for research purposes only. |
|